Maroua Belghali
Nathalie Chastan1,2
Damien Davenne
Leslie M. Decker- 1Normandie Université, UNICAEN, INSERM, COMETE, Caen, France
- 2Department of Neurophysiology, Normandie Université, UNIROUEN, Rouen University Hospital-Charles Nicolle, Rouen, France
Gait control is a complex movement, relying on spinal, subcortical, and cortical structures. The presence of deficits in one or more of these structures will result in changes in gait automaticity and control, as is the case in several neurodegenerative diseases, such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). By reviewing recent findings in this field of research, current studies have shown that gait performance assessment under dual-task conditions could contribute to predict both of these diseases. Such suggestions are relevant mainly for people at putatively high risk of developing AD (i.e., older adults with mild cognitive impairment subtypes) or PD (i.e., older adults with either Mild Parkinsonian signs or LRRK2 G2019S mutation). Despite the major importance of these results, the type of cognitive task that should be used as a concurrent secondary task has to be selected among the plurality of tasks proposed in the literature. Furthermore, the key aspects of gait control that represent sensitive and specific “gait signatures” for prodromal AD or PD need to be determined. In the present perspective article, we suggest the use of a Stroop interference task requiring inhibitory attentional control and a set-shifting task requiring reactive flexibility as being particularly relevant secondary tasks for challenging gait in prodromal AD and PD, respectively. Investigating how inhibition and cognitive flexibility interfere with gait control is a promising avenue for future research aimed at enhancing early detection of AD and PD, respectively.
Gait control is a complex movement involving a large class of processes, from sensory integration to movement execution and internal models of action. These processes rely on spinal, subcortical, and cortical structures (1). The presence of deficits in one or more of these structures will result in changes in gait automaticity and control, as is the case in several neurodegenerative diseases such as Alzheimer’s disease (AD) (2) and Parkinson’s disease (PD) (3).
To date, AD and PD are diagnosed in the advanced stage of degenerative brain processes, when clinical symptoms occur. In the absence of curative therapy, current research is focused on prevention by identifying subtle signs of early stage neurodegeneration. Crucially, early diagnosis would provide a critical opportunity for disease-modulating interventions targeting modifiable risk factors for AD or PD (4), or even neuro-protective therapies, both of which would help delay, slow, or even prevent disease progression [i.e., more cases would remain in the mild stage rather than degrading to moderate or severe stages (5)]. These risk factors are modifiable by making lifestyle changes (e.g., greater participation in physically and intellectually stimulating activities, social engagement, balanced diet with a high proportion of unsaturated fatty acids) and/or treating long-term health conditions (e.g., excessively high or low blood pressure, insufficient and/or fragmented sleep, diabetes, midlife obesity).
In the light of these clinical perspectives, increasing evidence supports the idea that the neuropathological process underlying PD and AD begins long before the onset of clinical symptoms as currently defined. In PD, longitudinal studies have shown that idiopathic rapid-eye-movement sleep behavior disorder (IRBD) appears 26 years before diagnosis (6), followed by anxiety (up to 20 years), and reduced gastrointestinal motility and olfaction [up to 12 years (7)]. In AD, other longitudinal studies have shown that depression appears more than 10 years before the onset of AD (8), followed by memory complaints [at least 9–10 years (9)] and mild cognitive impairment (MCI) [up to 6 years (10)]. Nonetheless, these symptoms are non-specific to these diseases, i.e., the presence of any of these symptoms does not necessarily lead to progression to these diseases. However, longitudinal data have confirmed that people with IRBD are at higher risk of conversion to PD [81% after 26 years (6)] and persons with amnesic MCI and multi-domain MCI are at higher risk of conversion to AD [80% after 6 years (10)]. Despite these findings, clinicians do not have available prodromal markers allowing them to identify MCI and IRBD patients who will develop AD or PD. In these populations, in spite of remarkable developments in neuroimaging, genetics, and molecular biomarkers, there is still an urgent need for disease-specific prodromal markers [referring to “signatures” of an ongoing pathological process prior to the presence of typical symptoms, thus allowing clinical diagnosis (11)]. Recent research focusing on such markers has already found that gait control under dual-task conditions [i.e., referring to a situation in which a secondary cognitive task is performed concurrently with a primary task while walking (12)] could contribute to predicting AD and PD in their prodromal phases (3, 13).
To summarize, both PD and AD share a long prodromal phase in which gait control under dual-task conditions is already altered. Given that the neuropathological profile of PD differs from AD, the question arises as to whether the dual-task walking paradigm is sensitive enough to identify disease-specific gait patterns. To our knowledge, this question has not been addressed in the literature. In this perspective article, we first report results supporting the idea that changes in gait control may constitute early, non-invasive, and sensitive prodromal markers of underlying neurodegeneration in PD and AD (Figure 1A). Second, we propose two dual-task models that could help specifically detect these two diseases (Figure 1B).
Figure 1. (A) Relevance of dual-task paradigms in detecting gait disorders in preclinical Alzheimer’s disease (AD) and Parkinson’s disease (PD). Gait disorders are characteristic features of AD (gray, left side) and PD (blue, right side) and can be unmasked under dual-task conditions. These disorders could arise from different neuropathological mechanisms in the preclinical stage, as impaired prefrontal cortex function in AD and impaired basal ganglia function in PD, and alter attentional control of gait in AD (i.e., “cortical gait disorders”) and automaticity of gait in PD (i.e., “cortical-subcortical gait disorders”). (B) Suggestions for choice of cognitive tasks and gait parameters. Dual-task gait assessment using targeted cognitive tasks (i.e., inhibitory control for AD, and cognitive flexibility for PD), taking into account task prioritization (trade-off effects) and factors known to modulate susceptibility to dual-task interference (age, gender, processing speed, stress, and cognitive reserve) would be valuable for enhancing detection of prodromal AD and PD.
Dual-Task-Related Gait Changes in Prodromal PD
Parkinson’s disease is manifested by loss of dopamine-secreting neurons in the substantia nigra (14), leading to a lack of dopamine in the striatum and causing disruption of the basal ganglia circuit (15). At the behavioral level, it is widely accepted that gait deficits are among the most important motor problems associated with PD. The latter are characterized by deficits in all spatio-temporal gait parameters (16), rhythmic limb movements (17), arm swing amplitude and symmetry (18), bilateral arm coordination (19), and adjustment of postural muscle tone (20). Mechanistically, gait deficits may result from a mixture of several factors including: (i) a loss of motor automaticity mediated by impaired internal cueing mechanisms and less effective connectivity between motor areas (21), (ii) use of attentional control strategies in order to bypass impaired automatic motor processes (21), (iii) impaired motor planning mediated by decreased activity in the caudal cingulate motor area (22), (iv) axial rigidity mediated by exaggeration of long-latency reflexes (23), (v) cognitive inflexibility mediated by changes in frontal-striatal circuits (24, 25), and (vi) the inability to use a “posture-first” strategy (i.e., prioritizing gait over other concurrent tasks). The presence of non-dopaminergic pathology, such as serotonin, norepinephrine or acetylcholine, and muscle weakness may also explain gait deficits in PD (16).
In contradiction with these findings, some studies (26, 27) found that certain aspects of gait such as gait speed and step length were unexpectedly unaffected under dual-task conditions. According to the review by Bloem et al. (28), PD patients improved their gait performance by using external cues allowing the frontal cortex to compensate for the defective basal ganglia circuitry (28–30). Another possible explanation is that PD patients were able to prioritize gait to the detriment of cognitive tasks [“posture-first” strategy (28, 31)]. Recently, the study by Rochester et al. (31) suggests that the use of an auditory cognitive task may also improve the gait performance of PD patients. Such a modality may also provide beneficial cueing effects on gait rhythm through compensatory mechanisms or by facilitating task prioritization (31).
At present, the onset of PD appears after depletion of 70–80% of striatal dopamine, corresponding to 30–50% of dead cells of dopaminergic neurons (3). Clinically, gait deficits that should appear because of basal ganglia dysfunction and loss of dopamine are not detectable under undisturbed walking conditions (i.e., self-selected comfortable speed under single-task condition) in prodromal PD (32). This might be due to satisfactory compensatory mechanisms in the motor system which compensate for the slowly progressing nigrostriatal dopamine depletion, both within and outside the basal ganglia (33). It has been suggested that dual-task walking might be a valuable tool for unmasking the use of compensatory strategies (32, 34, 35). Currently, all studies (n = 3) conducted in the prodromal stage of PD support this view. The first study by Lerche et al. (35) showed that individuals with mild parkinsonian signs slowed down to the same extent as non-demented patients with PD when performing dual-task walking. The two other studies (34, 36) showed increasing in-stride time variability, arm swing asymmetry, and arm swing variability under dual-task walking conditions in LRRK2 G2019S mutation carriers without a clinical diagnosis of PD. To our knowledge, no study has been conducted in IRBD.
Given the limited number of studies focusing on gait in the prodromal phase of PD, the exact mechanisms underlying dual-task-related gait changes remain unclear. Nonetheless, it is likely that these changes reflect early impairment of motor automaticity due to an early dysfunction in basal ganglia–brainstem pathways (34, 35) and cognitive inflexibility (35). Thus, we suggest that frontal–striatal network deficits involved in both cognitive flexibility and gait automaticity could be considered as possible mechanisms contributing to dual-task-related gait changes in prodromal PD. Besides, we suggest that limited attentional capacities could also prevent patients from sharing attention (i.e., central capacity sharing model) and/or correctly processing the attentional demands of each task (i.e., central bottleneck model). Indeed, the central bottleneck model postulates that central processing acts on only one task at a time, and therefore, constitutes a bottleneck that processes tasks serially (37, 38), whereas the central capacity sharing model claims that the central stage is a limited-capacity parallel processor that divides resources among to-be-performed tasks (39, 40).
Dual-Task-Related Gait Changes in Prodromal AD
Alzheimer’s disease is characterized by the presence of both amyloid beta plaques and neurofibrillary tangles [i.e., the two hallmark pathologies (41, 42)] in the medial temporal lobe structures (particularly the hippocampus) and neocortex, together with neuronal loss and volume reductions (43, 44). At behavioral level, AD is characterized by marked impairment in several cognitive domains including the episodic, working and semantic memories, visuo-spatial abilities, language, and executive attention control (45, 46). Interestingly, these cognitive impairments affect gait control (1, 47–50). From the literature, the picture emerges that deficits in cognition are manifested through subtle gait control deficits in pace (i.e., step velocity, step length, step time variability, swing time variability, stance time variability) and variability (i.e., step velocity variability, step length variability, step width variability) domains of gait (50). In addition, other studies suggest that the hyperexcitability of the motor cortex may also contribute to gait deficits in clinical AD.
An autopsy study on brains from non-demented and demented individuals (43) has shown that extracellular amyloid deposition usually appears before any intraneuronal neurofibrillary changes, first in the entorhinal cortex before spreading in a hierarchical manner into the hippocampus proper and cortex (43). A longitudinal neuropsychological study of the transition from healthy aging to AD (51) revealed that impairment in executive attention control, particularly inhibition [i.e., ability to deliberately inhibit dominant, automatic, or prepotent responses when required and/or requested (52)], precedes impairment in episodic memory in the course of the disease and, importantly, predicts AD. The recent neuroimaging study by Harrington et al. (53) has shown that abnormal extracellular amyloid accumulation in the basal isocortex impairs inhibition [as assessed by the Stroop task (54)] in asymptomatic individuals with abnormal beta-amyloid 42/tau ratios. It is worth mentioning that the underlying pathways of inhibition include the bilateral dorsolateral prefrontal cortex, inferior frontal gyrus, anterior cingulate cortex, and posterior parietal cortex (55). Collectively, these findings suggest that prefrontal dysfunction is present during the early stages (preclinical) of AD (53).
At the onset of MCI (i.e., prodromal phase of AD), the neuropathological mechanisms underlying progression to AD become more complex. Nevertheless, several studies have demonstrated reduced hippocampal and entorhinal cortex volume, as well as reduced cortical thickness in the medial and lateral temporal cortex, parietal lobe, and frontal lobes in MCI patients who have converted to AD (MCI-converters), up to 2 years prior to clinical conversion, as compared to MCI patients who remained stable (MCI-stable) (56–59). At the behavioral level, longitudinal studies found that MCI-converters performed worse than controls on measurements of episodic and working memory (60) and of executive attention control, particularly inhibition (61). Hence, it is likely that executive inhibitory control could also represent a hallmark of early AD.
Anatomically, the prefrontal cortex plays a major role not only in executive attention control but also in gait control through its connection with the striatum (62). Thus, one could hypothesize that changes in executive attention control should be reflected in gait, notably when having to devote attentional resources to a simultaneously performed secondary task. Several studies using dual-task walking paradigms support this view. Clinically, the fact that changes in executive attention control can be measured through dual-task assessment has opened up a new line of research devoted to identify a “gait phenotype” of abnormal cognitive decline due to underlying AD or other types of dementia (2). Unfortunately, to date, no studies using the dual-task walking paradigm have been conducted at the preclinical stage of AD. However, several cross-sectional studies have been performed at the prodromal stage among various MCI patient subtypes. Findings revealed that walking under dual-task conditions induced differential changes in gait velocity and variability of various spatio-temporal parameters (13, 63–67). Such changes, named “cortical gait disorders,” have been interpreted to reveal impairments in both working memory and executive attention control (67). Studies using magnetic resonance spectroscopy in MCI patients showed that dual-task-related gait changes are associated with changed neurochemistry (i.e., lower N-acetyl aspartate/creatine) and lower hippocampal and primary motor cortex volumes (68). Other interpretations are the central bottleneck and central capacity sharing models (37–40).
Collectively, these findings suggest that the neuropathological mechanisms underlying dual-task-related gait changes in MCI patients may result from a combination of several factors. However, recent studies support the idea that impairments in both frontal–hippocampal circuits [involved in spatial orientation and navigation (64)] and prefrontal–striatal circuits [involved in executive attention control (2)] may potentially contribute to gait deficits.
Importantly, in contrast to the above findings, two studies found a pattern of dual-task interference in MCI patients that was not significantly different from healthy older adults (69, 70) since both groups became slower and more variable during dual-task walking. Although not reported by the authors, one can speculate that not all of the MCI patients would have converted to dementia. Therefore, it remains highly plausible that the use of dual-task gait assessment could allow improved discrimination between converters and non-converters. A longitudinal study has provided evidence supporting this hypothesis (71), by showing that MCI-converters reduced gait speed and increased gait variability under dual-task conditions more than non-converters. However, additional longitudinal studies are needed to confirm these findings.
How Could Dual-Task Gait Assessment be Improved to be Used Potentially as a Robust and Clinically Relevant Marker of Prodromal AD or PD?
As discussed above, dual-task-related gait decrements may provide a powerful prodromal marker of neurodegenerative diseases, such as AD and PD. However, the use of dual-task paradigm in clinical practice requires further clarifications on some methodological aspects. First, the type of cognitive task to be used as a concurrent secondary task has to be selected among the plurality of tasks proposed in the literature. Second, the key aspects of gait control that represent sensitive and specific “gait signatures” for prodromal AD or PD need to be determined. Third, interindividual differences in factors known to play a strong role in shaping expression and timing of onset of disease should be taken into account when analyzing dual-task performance.
Suggestions for Future Research Directions
Dual-task-related gait changes may vary depending on the type of secondary cognitive task. Previous literature suggests that cognitive tasks involving internal interfering factors seem to disturb gait performance more than those involving external interfering factors (72). The modality of the secondary cognitive task may also influence gait performance, particularly in PD patients who are less sensitive to dual-task interference under the auditory modality. In our view, a way to make better use of dual-task walking paradigms is to select a secondary cognitive task that both interferes with gait control and challenges the underlying neuropathological processes (in favor of the bottleneck model). Since specific impairments are found in inhibition for AD (51, 53) and cognitive flexibility for PD (35), we suggest the use of a visual Stroop interference task requiring executive inhibitory control (73) and a visual set-shifting task requiring reactive flexibility (74) as particularly relevant secondary tasks for challenging gait in prodromal AD and PD, respectively. Such tasks are known to interfere with gait control (50, 75) and importantly, begin to deteriorate years prior to the onset of the first clinical symptoms. Moreover, cognitive flexibility and inhibition depend on dopamine function in the basal ganglia (76) and entorhinal cortex (77), respectively (Figure 1B). In order to reduce patient stress induced by dual-task gait assessment, virtual environments using embedded secondary cognitive tasks appear to offer a good solution due to their ecological character (78).
Regarding the choice of gait parameters, lower-limb gait parameters have been widely studied and characterized, whereas less is known about upper-limb gait parameters in both AD and PD. However, previous studies have highlighted that deficits in the latter parameters (e.g., arm swing amplitude and symmetry, bilateral arm coordination) are characteristic features of PD. Surprisingly, these upper-limb gait parameters, known to be linked to dysfunction of basal ganglia (18, 19, 79, 80), were explored in only one study in the prodromal stage of PD (36). Therefore, investigating how gait parameters related to basal ganglia dysfunction change in prodromal PD is a useful approach that should be considered in future studies.
In response to the need for theoretical development in measuring dual-task performance, Plummer et al. (81, 82) have proposed an elegant conceptual model for pattern classification of dual-task interference by assessing the interactions between two simultaneously performed tasks (i.e., trade-off strategy). In addition, we would argue that it is also imperative to take into account factors modulating the capacity to cope with a concurrent cognitive load while walking, among which the most important are age, gender, processing speed (83), stress, and cognitive reserve [i.e., the background cognitive capacity that a subject brings to a given task (84)]. Applying these methodological recommendations for the conduct of future research would likely enhance the reliability of dual-task gait assessment and its large-scale application in clinical practice.
More broadly, the only study design approach allowing identification of robust, clinically relevant gait markers for preclinical AD or PD consists in longitudinal studies aimed at comparing patients from complaints to disease expression (preclinical, prodromal, and clinical) from those who will remain stable. To date, no such studies have been conducted on patients with cognitive complaints and/or IRBD, and only one has been carried out on MCI, although without a control group.
In conclusion, we can consider dual-task-related changes in gait control, taking into account task prioritization (trade-off effects) and factors known to modulate susceptibility to dual-task interference, as potential markers for prodromal neurodegeneration. Investigating how inhibition and cognitive flexibility interfere with gait control is a promising avenue for future research aimed at enhancing early detection of AD and PD, respectively. Longitudinal studies and standardized protocols would certainly ensure consistency and aid interpretation.
Author Contributions
MB and LMD wrote the manuscript. NC and DD revised it critically for important intellectual content. All authors approved its final version and contributed to the conceptual figure.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Funding
This work was supported by the French National Institute of Health and Medical Research (INSERM), the Regional Council of Basse-Normandie, and the University of Caen Normandie.
References
1. Beauchet O, Allali G, Berrut G, Hommet C, Dubost V, Assal F. Gait analysis in demented subjects: interests and perspectives. Neuropsychiatr Dis Treat (2008) 4:155–60. doi: 10.2147/NDT.S2070
2. Beauchet O, Allali G, Montero-Odasso M, Sejdić E, Fantino B, Annweiler C. Motor phenotype of decline in cognitive performance among community-dwellers without dementia: population-based study and meta-analysis. PLoS One (2014) 9:e99318. doi:10.1371/journal.pone.0099318
3. Postuma RB, Aarsland D, Barone P, Burn DJ, Hawkes CH, Oertel W, et al. Identifying prodromal Parkinson’s disease: pre-motor disorders in Parkinson’s disease. Mov Disord (2012) 27:617–26. doi:10.1002/mds.24996
4. Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer’s disease prevalence. Lancet Neurol (2011) 10:819–28. doi:10.1016/S1474-4422(11)70072-2
5. Petersen RC. Early diagnosis of Alzheimer’s disease: is MCI too late? Curr Alzheimer Res (2009) 6:324–30. doi:10.2174/156720509788929237
6. Schenck CH, Boeve BF, Mahowald MW. Delayed emergence of a parkinsonian disorder or dementia in 81% of older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder: a 16-year update on a previously reported series. Sleep Med (2013) 14:744–8. doi:10.1016/j.sleep.2012.10.009
7. Gaenslen A, Swid I, Liepelt-Scarfone I, Godau J, Berg D. The patients’ perception of prodromal symptoms before the initial diagnosis of Parkinson’s disease. Mov Disord (2011) 26:653–8. doi:10.1002/mds.23499
8. Speck CE, Kukull WA, Brenner DE, Bowen JD, McCormick WC, Teri L, et al. History of depression as a risk factor for Alzheimer’s disease. Epidemiology (1995) 6:366–9. doi:10.1097/00001648-199507000-00006
9. Amieva H, Jacqmin-Gadda H, Orgogozo J-M, Carret NL, Helmer C, Letenneur L, et al. The 9 year cognitive decline before dementia of the Alzheimer type: a prospective population-based study. Brain (2005) 128:1093–101. doi:10.1093/brain/awh451
10. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, et al. Current concepts in mild cognitive impairment. Arch Neurol (2001) 58:1985–92. doi:10.1001/archneur.58.12.1985
11. Heinzel S, Roeben B, Ben-Shlomo Y, Lerche S, Alves G, Barone P, et al. Prodromal markers in Parkinson’s disease: limitations in longitudinal studies and lessons learned. Front Aging Neurosci (2016) 8:147. doi:10.3389/fnagi.2016.00147
12. Montero-Odasso M, Muir SW, Hall M, Doherty TJ, Kloseck M, Beauchet O, et al. Gait variability is associated with frailty in community-dwelling older adults. J Gerontol A Biol Sci Med Sci (2011) 66:568–76. doi:10.1093/gerona/glr007
13. Montero-Odasso M, Oteng-Amoako A, Speechley M, Gopaul K, Beauchet O, Annweiler C, et al. The motor signature of mild cognitive impairment: results from the gait and brain study. J Gerontol A Biol Sci Med Sci (2014) 69:1415–21. doi:10.1093/gerona/glu155
15. Obeso JA, Marin C, Rodriguez-Oroz C, Blesa J, Benitez-Temiño B, Mena-Segovia J, et al. The basal ganglia in Parkinson’s disease: current concepts and unexplained observations. Ann Neurol (2008) 64(Suppl 2):S30–46. doi:10.1002/ana.21481
16. Kelly VE, Eusterbrock AJ, Shumway-Cook A. A review of dual-task walking deficits in people with Parkinson’s disease: motor and cognitive contributions, mechanisms, and clinical implications. Parkinsons Dis (2012) 2012:918719. doi:10.1155/2012/918719
17. Roemmich RT, Field AM, Elrod JM, Stegemöller EL, Okun MS, Hass CJ. Interlimb coordination is impaired during walking in persons with Parkinson’s disease. Clin Biomech (Bristol Avon) (2013) 28:93–7. doi:10.1016/j.clinbiomech.2012.09.005
18. Lewek MD, Poole R, Johnson J, Halawa O, Huang X. Arm swing magnitude and asymmetry during gait in the early stages of Parkinson’s disease. Gait Posture (2010) 31:256–60. doi:10.1016/j.gaitpost.2009.10.013
19. Sterling NW, Cusumano JP, Shaham N, Piazza SJ, Liu G, Kong L, et al. Dopaminergic modulation of arm swing during gait among Parkinson’s disease patients. J Parkinsons Dis (2015) 5:141–50. doi:10.3233/JPD-140447
20. Takakusaki K, Saitoh K, Harada H, Kashiwayanagi M. Role of basal ganglia-brainstem pathways in the control of motor behaviors. Neurosci Res (2004) 50:137–51. doi:10.1016/j.neures.2004.06.015
21. Wu T, Hallett M, Chan P. Motor automaticity in Parkinson’s disease. Neurobiol Dis (2015) 82:226–34. doi:10.1016/j.nbd.2015.06.014
22. Snijders AH, Leunissen I, Bakker M, Overeem S, Helmich RC, Bloem BR, et al. Gait-related cerebral alterations in patients with Parkinson’s disease with freezing of gait. Brain (2011) 134:59–72. doi:10.1093/brain/awq324
23. Mazzoni P, Shabbott B, Cortés JC. Motor control abnormalities in Parkinson’s disease. Cold Spring Harb Perspect Med (2012) 2:a009282. doi:10.1101/cshperspect.a009282
24. Kehagia AA, Barker RA, Robbins TW. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson’s disease. Lancet Neurol (2010) 9:1200–13. doi:10.1016/S1474-4422(10)70212-X
25. Cools R. Dopaminergic modulation of cognitive function-implications for l-DOPA treatment in Parkinson’s disease. Neurosci Biobehav Rev (2006) 30:1–23. doi:10.1016/j.neubiorev.2005.03.024
26. Rochester L, Galna B, Lord S, Burn D. The nature of dual-task interference during gait in incident Parkinson’s disease. Neuroscience (2014) 265:83–94. doi:10.1016/j.neuroscience.2014.01.041
27. Kelly VE, Shumway-Cook A. The ability of people with Parkinson’s disease to modify dual-task performance in response to instructions during simple and complex walking tasks. Exp Brain Res (2014) 232:263–71. doi:10.1007/s00221-013-3737-4
28. Bloem BR, Grimbergen YA, van Dijk JG, Munneke M. The “posture second” strategy: a review of wrong priorities in Parkinson’s disease. J Neurol Sci (2006) 248:196–204. doi:10.1016/j.jns.2006.05.010
29. Morris ME, Iansek R, Matyas TA, Summers JJ. The pathogenesis of gait hypokinesia in Parkinson’s disease. Brain (1994) 117(Pt 5):1169–81. doi:10.1093/brain/117.5.1169
30. Kitamura J, Nakagawa H, Iinuma K, Kobayashi M, Okauchi A, Oonaka K, et al. Visual influence on center of contact pressure in advanced Parkinson’s disease. Arch Phys Med Rehabil (1993) 74:1107–12. doi:10.1016/0003-9993(93)90070-Q
31. Rochester L, Nieuwboer A, Baker K, Hetherington V, Willems A-M, Kwakkel G, et al. Walking speed during single and dual tasks in Parkinson’s disease: which characteristics are important? Mov Disord (2008) 23:2312–8. doi:10.1002/mds.22219
32. Panyakaew P, Bhidayasiri R. The spectrum of preclinical gait disorders in early Parkinson’s disease: subclinical gait abnormalities and compensatory mechanisms revealed with dual tasking. J Neural Transm (Vienna) (2013) 120:1665–72. doi:10.1007/s00702-013-1051-8
33. Bezard E, Fernagut P-O. Premotor parkinsonism models. Parkinsonism Relat Disord (2014) 20(Suppl 1):S17–9. doi:10.1016/S1353-8020(13)70007-5
34. Mirelman A, Gurevich T, Giladi N, Bar-Shira A, Orr-Urtreger A, Hausdorff JM. Gait alterations in healthy carriers of the LRRK2 G2019S mutation. Ann Neurol (2011) 69:193–7. doi:10.1002/ana.22165
35. Lerche S, Hobert M, Brockmann K, Wurster I, Gaenslen A, Hasmann S, et al. Mild parkinsonian signs in the elderly – is there an association with PD? Crossectional findings in 992 individuals. PLoS One (2014) 9:e92878. doi:10.1371/journal.pone.0092878
36. Mirelman A, Bernad-Elazari H, Thaler A, Giladi-Yacobi E, Gurevich T, Gana-Weisz M, et al. Arm swing as a potential new prodromal marker of Parkinson’s disease. Mov Disord (2016) 31:1527–34. doi:10.1002/mds.26720
37. Pashler H. Processing stages in overlapping tasks: evidence for a central bottleneck. J Exp Psychol Hum Percept Perform (1984) 10:358–77. doi:10.1037/0096-1523.10.3.358
38. Pashler H. Dual-task interference in simple tasks: data and theory. Psychol Bull (1994) 116:220–44. doi:10.1037/0033-2909.116.2.220
39. Montero-Odasso M, Casas A, Hansen KT, Bilski P, Gutmanis I, Wells JL, et al. Quantitative gait analysis under dual-task in older people with mild cognitive impairment: a reliability study. J Neuroeng Rehabil (2009) 6:35. doi:10.1186/1743-0003-6-35
40. Tombu M, Jolicoeur P. A central capacity sharing model of dual-task performance. J Exp Psychol Hum Percept Perform (2003) 29:3–18. doi:10.1037/0096-1523.29.1.3
41. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer’s disease. Lancet (2011) 377:1019–31. doi:10.1016/S0140-6736(10)61349-9
42. Ittner LM, Götz J. Amyloid-β and tau – a toxic pas de deux in Alzheimer’s disease. Nat Rev Neurosci (2011) 12:65–72. doi:10.1038/nrn2967
43. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (1991) 82:239–59. doi:10.1007/BF00308809
44. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, et al. Physical basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol (1991) 30:572–80. doi:10.1002/ana.410300410
45. Nordahl CW, Ranganath C, Yonelinas AP, Decarli C, Fletcher E, Jagust WJ. White matter changes compromise prefrontal cortex function in healthy elderly individuals. J Cogn Neurosci (2006) 18:418–29. doi:10.1162/089892906775990552
46. Mayda AB, Westphal A, Carter CS, DeCarli C. Late life cognitive control deficits are accentuated by white matter disease burden. Brain (2011) 134:1673–83. doi:10.1093/brain/awr065
47. van Iersel MB, Kessels RP, Bloem BR, Verbeek AL, Olde Rikkert MG. Executive functions are associated with gait and balance in community-living elderly people. J Gerontol A Biol Sci Med Sci (2008) 63:1344–9. doi:10.1093/gerona/63.12.1344
48. Sheridan PL, Hausdorff JM. The role of higher-level cognitive function in gait: executive dysfunction contributes to fall risk in Alzheimer’s disease. Dement Geriatr Cogn Disord (2007) 24:125–37. doi:10.1159/000105126
49. Coelho FG, Stella F, de Andrade LP, Barbieri FA, Santos-Galduróz RF, Gobbi S, et al. Gait and risk of falls associated with frontal cognitive functions at different stages of Alzheimer’s disease. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn (2012) 19:644–56. doi:10.1080/13825585.2012.661398
50. Morris R, Lord S, Bunce J, Burn D, Rochester L. Gait and cognition: mapping the global and discrete relationships in ageing and neurodegenerative disease. Neurosci Biobehav Rev (2016) 64:326–45. doi:10.1016/j.neubiorev.2016.02.012
51. Balota DA, Tse C-S, Hutchison KA, Spieler DH, Duchek JM, Morris JC. Predicting conversion to dementia of the Alzheimer type in a healthy control sample: the power of errors in Stroop color naming. Psychol Aging (2010) 25:208–18. doi:10.1037/a0017474
52. Miyake A, Friedman NP, Emerson MJ, Witzki AH, Howerter A, Wager TD. The unity and diversity of executive functions and their contributions to complex “Frontal Lobe” tasks: a latent variable analysis. Cogn Psychol (2000) 41:49–100. doi:10.1006/cogp.1999.0734
53. Harrington MG, Chiang J, Pogoda JM, Gomez M, Thomas K, Marion SD, et al. Executive function changes before memory in preclinical Alzheimer’s pathology: a prospective, cross-sectional, case control study. PLoS One (2013) 8:e79378. doi:10.1371/journal.pone.0079378
54. Stroop JR. Studies of interference in serial verbal reactions. J Exp Psychol (1935) 18:643–62. doi:10.1037/h0054651
55. Nee DE, Wager TD, Jonides J. Interference resolution: insights from a meta-analysis of neuroimaging tasks. Cogn Affect Behav Neurosci (2007) 7:1–17. doi:10.3758/CABN.7.1.1
56. deToledo-Morrell L, Stoub TR, Bulgakova M, Wilson RS, Bennett DA, Leurgans S, et al. MRI-derived entorhinal volume is a good predictor of conversion from MCI to AD. Neurobiol Aging (2004) 25:1197–203. doi:10.1016/j.neurobiolaging.2003.12.007
57. Devanand DP, Liu X, Tabert MH, Pradhaban G, Cuasay K, Bell K, et al. Combining early markers strongly predicts conversion from mild cognitive impairment to Alzheimer’s disease. Biol Psychiatry (2008) 64:871–9. doi:10.1016/j.biopsych.2008.06.020
58. Jack CR, Petersen RC, Xu YC, O’Brien PC, Smith GE, Ivnik RJ, et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology (1999) 52:1397–403. doi:10.1212/WNL.52.7.1397
59. Risacher SL, Shen L, West JD, Kim S, McDonald BC, Beckett LA, et al. Longitudinal MRI atrophy biomarkers: relationship to conversion in the ADNI cohort. Neurobiol Aging (2010) 31:1401–18. doi:10.1016/j.neurobiolaging.2010.04.029
60. Cloutier S, Chertkow H, Kergoat M-J, Gauthier S, Belleville S. Patterns of cognitive decline prior to dementia in persons with mild cognitive impairment. J Alzheimers Dis (2015) 47:901–13. doi:10.3233/JAD-142910
61. Belleville S, Chertkow H, Gauthier S. Working memory and control of attention in persons with Alzheimer’s disease and mild cognitive impairment. Neuropsychology (2007) 21:458–69. doi:10.1037/0894-4105.21.4.458
62. Pugh KG, Lipsitz LA. The microvascular frontal-subcortical syndrome of aging. Neurobiol Aging (2002) 23:421–31. doi:10.1016/S0197-4580(01)00319-0
63. Pettersson AF, Olsson E, Wahlund L-O. Effect of divided attention on gait in subjects with and without cognitive impairment. J Geriatr Psychiatry Neurol (2007) 20:58–62. doi:10.1177/0891988706293528
64. Montero-Odasso M, Muir SW, Speechley M. Dual-task complexity affects gait in people with mild cognitive impairment: the interplay between gait variability, dual tasking, and risk of falls. Arch Phys Med Rehabil (2012) 93:293–9. doi:10.1016/j.apmr.2011.08.026
65. Doi T, Shimada H, Makizako H, Tsutsumimoto K, Uemura K, Anan Y, et al. Cognitive function and gait speed under normal and dual-task walking among older adults with mild cognitive impairment. BMC Neurol (2014) 14:67. doi:10.1186/1471-2377-14-67
66. Montero-Odasso M. Gait as a biomarker of cognitive impairment and dementia syndromes. Quo vadis? Eur J Neurol (2016) 23:437–8. doi:10.1111/ene.12908
67. Maquet D, Lekeu F, Warzee E, Gillain S, Wojtasik V, Salmon E, et al. Gait analysis in elderly adult patients with mild cognitive impairment and patients with mild Alzheimer’s disease: simple versus dual task: a preliminary report. Clin Physiol Funct Imaging (2010) 30:51–6. doi:10.1111/j.1475-097X.2009.00903.x
68. Annweiler C, Beauchet O, Bartha R, Wells JL, Borrie MJ, Hachinski V, et al. Motor cortex and gait in mild cognitive impairment: a magnetic resonance spectroscopy and volumetric imaging study. Brain (2013) 136:859–71. doi:10.1093/brain/aws373
69. Nascimbeni A, Caruso S, Salatino A, Carenza M, Rigano M, Raviolo A, et al. Dual task-related gait changes in patients with mild cognitive impairment. Funct Neurol (2015) 30:59–65. doi:10.11138/FNeur/2015.30.1.059
70. Pettersson AF, Olsson E, Wahlund L-O. Motor function in subjects with mild cognitive impairment and early Alzheimer’s disease. Dement Geriatr Cogn Disord (2005) 19:299–304. doi:10.1159/000084555
71. Gillain S, Dramé M, Lekeu F, Wojtasik V, Ricour C, Croisier J-L, et al. Gait speed or gait variability, which one to use as a marker of risk to develop Alzheimer disease? A pilot study. Aging Clin Exp Res (2016) 28:249–55. doi:10.1007/s40520-015-0392-6
72. Al-Yahya E, Dawes H, Smith L, Dennis A, Howells K, Cockburn J. Cognitive motor interference while walking: a systematic review and meta-analysis. Neurosci Biobehav Rev (2011) 35:715–28. doi:10.1016/j.neubiorev.2010.08.008
73. Seo EH, Kim H, Lee KH, Choo IH. Altered executive function in pre-mild cognitive impairment. J Alzheimers Dis (2016) 54:933–40. doi:10.3233/JAD-160052
74. Cools R, Barker RA, Sahakian BJ, Robbins TW. Mechanisms of cognitive set flexibility in Parkinson’s disease. Brain (2001) 124:2503–12. doi:10.1093/brain/124.12.2503
75. Strouwen C, Molenaar EA, Keus SH, Münks L, Heremans E, Vandenberghe W, et al. Are factors related to dual-task performance in people with Parkinson’s disease dependent on the type of dual task? Parkinsonism Relat Disord (2016) 23:23–30. doi:10.1016/j.parkreldis.2015.11.020
76. Berry AS, Shah VD, Baker SL, Vogel JW, O’Neil JP, Janabi M, et al. Aging affects dopaminergic neural mechanisms of cognitive flexibility. J Neurosci (2016) 36:12559–69. doi:10.1523/JNEUROSCI.0626-16.2016
77. Velayudhan L, Proitsi P, Westman E, Muehlboeck J-S, Mecocci P, Vellas B, et al. Entorhinal cortex thickness predicts cognitive decline in Alzheimer’s disease. J Alzheimers Dis (2013) 33:755–66. doi:10.3233/JAD-2012-121408
78. Lopez Maïté C, Gaétane D, Axel C. Ecological assessment of divided attention: what about the current tools and the relevancy of virtual reality. Rev Neurol (Paris) (2016) 172:270–80. doi:10.1016/j.neurol.2016.01.399
79. Huang X, Mahoney JM, Lewis MM, Guangwei Du, Piazza SJ, Cusumano JP. Both coordination and symmetry of arm swing are reduced in Parkinson’s disease. Gait Posture (2012) 35:373–7. doi:10.1016/j.gaitpost.2011.10.180
80. Isaias IU, Volkmann J, Marzegan A, Marotta G, Cavallari P, Pezzoli G. The influence of dopaminergic striatal innervation on upper limb locomotor synergies. PLoS One (2012) 7:e51464. doi:10.1371/journal.pone.0051464
81. Plummer P, Eskes G, Wallace S, Giuffrida C, Fraas M, Campbell G, et al. Cognitive-motor interference during functional mobility after stroke: state of the science and implications for future research. Arch Phys Med Rehabil (2013) 94:2565–74.e6. doi:10.1016/j.apmr.2013.08.002
82. Plummer P, Eskes G. Measuring treatment effects on dual-task performance: a framework for research and clinical practice. Front Hum Neurosci (2015) 9:225. doi:10.3389/fnhum.2015.00225
83. Sleimen-Malkoun R, Temprado J-J, Berton E. Age-related dedifferentiation of cognitive and motor slowing: insight from the comparison of Hick-Hyman and Fitts’ laws. Front Aging Neurosci (2013) 5:62. doi:10.3389/fnagi.2013.00062
Keywords: gait, dual-task, attention, executive function, Alzheimer’s disease, Parkinson’s disease, prodromal phase
Citation: Belghali M, Chastan N, Davenne D and Decker LM (2017) Improving Dual-Task Walking Paradigms to Detect Prodromal Parkinson’s and Alzheimer’s Diseases. Front. Neurol. 8:207. doi: 10.3389/fneur.2017.00207
Received: 23 February 2017; Accepted: 27 April 2017;
Published: 22 May 2017
Edited by:
Marco Schieppati, University of Pavia, ItalyCopyright: © 2017 Belghali, Chastan, Davenne and Decker. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Leslie M. Decker, bGVzbGllLmRlY2tlckB1bmljYWVuLmZy